News & Updates
Filter by Specialty:
TROPiCS-02: Sacituzumab govitecan offers HRQoL benefits in HR+/HER2- mBC
According to patient-reported outcomes (PROs) from the TROPiCS-02 study, sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) chemotherapy is associated with health-related quality of life (HRQoL) benefits across most symptoms and functioning domains among patients with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC).
TROPiCS-02: Sacituzumab govitecan offers HRQoL benefits in HR+/HER2- mBC
21 Sep 2024
Depemokimab a safe remedy for severe asthma exacerbations
Treatment with depemokimab results in a substantial decrease in exacerbations, with an acceptable safety profile, among severe asthma patients with an eosinophilic phenotype, results of the SWIFT-1 and 2 studies have shown.
Depemokimab a safe remedy for severe asthma exacerbations
20 Sep 2024
Benralizumab trumps steroids in treatment of asthma, COPD eosinophilic exacerbations
The time of steroids as the treatment of choice for asthma and chronic obstructive pulmonary disease (COPD) exacerbations appears to be nearing its end with the arrival of a new monoclonal antibody therapy, according to the results of the ABRA study.
Benralizumab trumps steroids in treatment of asthma, COPD eosinophilic exacerbations
20 Sep 2024
Lack of funds, staffing problem hinder program for kids with obesity
Several barriers on the system and organizational levels disrupt the continuous implementation of SmartMoves, an evidence-based intensive health behaviour and lifestyle treatment (IHBLT) program, for children with obesity, a study has shown.
